Fluorine-containing compound and anti-cancer medical use thereof
Summary
The USPTO granted patent US12595275B2 to Ascentawits Pharmaceuticals, Ltd. on April 7, 2026, covering a fluorine-containing compound (Formula II/III) with anti-cancer medical applications. The patent claims novel structures incorporating trifluoromethyl groups and fluorine-substituted aryl or heteroaryl groups at specific positions, with 17 total claims.
What changed
USPTO issued patent grant US12595275B2 to Ascentawits Pharmaceuticals, Ltd. for a fluorine-containing compound designed for anti-cancer applications. The compounds feature special trifluoromethyl groups and fluorine-substituted aryl/heteroaryl groups positioned between the nitrobenzene ring and phosphate amine group, resulting in solid-form compounds including waxes. The patent is classified under C07F 9/65583, C07F 9/564, A61P 35/00, and A61K 31/664.
For Ascentawits Pharmaceuticals, this grant provides 20-year exclusive rights to the patented compound and its anti-cancer use, effective from the May 12, 2020 filing date. Competitors in the pharmaceutical oncology space should monitor this IP position when developing similar fluorine-containing therapeutic compounds to avoid potential infringement exposure.
What to do next
- Monitor for updates
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Fluorine-containing compound and anti-cancer medical use thereof
Grant US12595275B2 Kind: B2 Apr 07, 2026
Assignee
ASCENTAWITS PHARMACEUTICALS, LTD.
Inventors
Jianxin Duan, Anrong Li, Fanying Meng, Xiaohong Cai
Abstract
Described is a fluorine-containing compound shown in Formula II/III and its anti-cancer medical use. The present application creatively introduced the fluorine-containing groups such as special trifluoromethyl groups, fluorine-substituted aryl groups, or heteroaryl groups at special positions (such as the position between the nitrobenzene ring and the phosphate amine group) in the structures of the above compounds. After this modification, it was found that all of the resulting compounds were solids (including waxes).
CPC Classifications
C07F 9/65583 C07F 9/564 A61P 35/00 A61K 31/664
Filing Date
2020-05-12
Application No.
17606476
Claims
17
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.